Ideaya Biosciences (IDYA) and Jiangsu Hengrui Pharmaceuticals Co. announced the publication of an abstract for an oral presentation on IDE849 at ...

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Overall, Hengrui invests more than 10% of its sales in R&D, “which is big by Chinese standards,” Tao says. The drug giant Pfizer by comparison spent about 15% of its sales on R&D in 2016.

Hengrui Pharma delivered a strong international presence, featuring 15 innovative drugs and 72 research outcomes. These included 4 oral presentations, 5 rapid oral presentations, 27 poster ...

A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg dose of the companies’ GLP-1/GIP receptor ...

Jiangsu Hengrui Pharmaceuticals Co. is considering a second listing in Hong Kong that could happen as soon as next year, according to people familiar with the situation.